The ocular pharmacokinetics of a new antibody (MIL60) against vascular endothelial growth factor (VEGF) following subconjunctival injection in rats
2018
Objective
To evaluate the ocular pharmacokinetics of a novel antibody, MIL60, targeting vascular endothelial growth factor (VEGF) after subconjunctival injection.
Methods
After subconjunctival injection of MIL60 in rabbits, aqueous humour, vitreous from both eyes and peripheral blood were collected of each rabbit to analyze the concentration of MIL60 with ELISA.
Results
After subconjunctival administration, MIL60 could penetrate into the injected eye′s anterior chamber and vitreous, and maintained at an effective concentration in the aqueous or vitreous for about 10.7 or 6.8 days. Moreover, MIL60 could be found in the uninjected eye.
Conclusion
After subconjunctival injection, MIL60 could maintain at a therapeutic concentration in injected eyes. The pharmacokinetics analysis of MIL60 might provide some basis and guidance for its application in humans in the near future.
Key words:
Pharmacokinetics; VEGF; Monoclonal antibody; Targeted antibody; Subconjunctival injection
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI